Coronavirus vaccine: DCGI gives nod to Serum-Oxford for phase 2, 3 clinical trials in India
(WorldNews India)

The Drugs Controller General of India (DCGI), country's top drug regulator, has allowed the Serum Institute of India (SII) to conduct phase 2 and 3 human clinical trials in India on the potential COVID19 vaccine, a senior government official said. "After a thorough evaluation, the DCGI has given approval to SII to perform phase-II, III clinical trial based on the recommendations of the Subject...